OPKO HEALTH, INC.

OPKO Health's subsidiary, OPKO Biologics, presented positive preclinical data for OPK8801001, a novel long-acting hGH receptor antagonist for acromegaly, at ENDO 2026. The data demonstrated robust, dose-dependent, and sustained suppression of IGF-1 in vivo, suggesting a potential once-weekly treatment option. Furthermore, in vitro studies showed OPK8801001 to be approximately 20-fold more potent than Pegvisomant, a current daily therapy, indicating a significant improvement in treatment burden for patients with this rare endocrine disorder.

OPKO Health, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time. Key proposals for shareholder vote include the election of eleven director nominees, approval of the 2026 Equity Incentive Plan, a non-binding advisory resolution on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026. The record date for stockholders entitled to vote is April 20, 2026, with 755,092,256 common shares outstanding.

OPKO Health, Inc. announced that its subsidiary EirGen Pharma Limited amended its agreement with Nicoya Therapeutics, granting OPKO a 15% equity stake in Nicoya. This amendment reinforces Nicoya's commitment to commercialize RAYALDEE in Greater China and expands the field of use. The original milestone structure, allowing OPKO to receive up to $115 million, remains unchanged. RAYALDEE is approved in Macau, with regulatory approvals expected in China and related territories in 2027, targeting a significant market of over 20 million adults with chronic kidney disease.

OPKO Health, Inc. reported a net loss of $(54.8) million, or $(0.07) per share, for Q1 2026, an improvement from a net loss of $(67.6) million, or $(0.10) per share, in Q1 2025. Total revenues decreased to $124.2 million from $149.9 million year-over-year, primarily due to the divestment of certain BioReference oncology diagnostics assets in September 2025. The company also repurchased $4.8 million of common stock during the quarter and is appealing a $246 million foreign tax assessment.

OPKO Health reported Q1 2026 total revenue of $124.2 million, a decrease from $149.9 million in Q1 2025, primarily due to the sale of BioReference assets. The company significantly narrowed its operating loss to $51.0 million from $67.2 million and net loss to $54.8 million ($0.07 per share) from $67.6 million ($0.10 per share) year-over-year. Key business highlights include the initiation of Phase 1 clinical trials for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma), expansion of a partnership with Entera Bio for an oral PTH tablet, and presentations of multispecific antibody data. The company also provided Q2 and full-year 2026 financial guidance.

OPKO Health reported Q1 2026 financial results, with consolidated total revenues of $124.2 million, down from $149.9 million YoY, primarily due to asset sales. However, the company significantly improved its operating loss to $51.0 million from $67.2 million and net loss to $54.8 million from $67.6 million. Operationally, OPKO initiated Phase 1 clinical trials for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma) and expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet, with an IND filing expected in late 2026. The company also provided Q2 and full-year 2026 financial guidance.

ModeX Therapeutics, an OPKO Health company, has begun dosing patients in a Phase 1 study for MDX2003, a novel T-cell engager for relapsed or refractory B-cell lymphoma. This first-in-class tetraspecific antibody targets CD19 and CD20 on cancer cells and CD3/CD28 on T-cells, aiming to optimize tumor killing and address immune escape. The study will assess safety, tolerability, and immune activity, marking a significant milestone for the company's pipeline.

OPKO Health, Inc. announced its plan to release operating and financial results for the first quarter ended March 31, 2026, after the U.S. financial markets close on Tuesday, April 28, 2026. Following the release, senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern time to provide a business update, discuss results, and offer financial guidance. Participants are encouraged to pre-register for the call.